Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N GRAFF

Showing results (71-80 of 104) with videos related to

Pageof 11
Sort By:
Neurology|April 28, 2012
Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memoryS Barral, T Bird, A Goate, et al.
Investigational New Drugs|November 29, 2014
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancerJoshi J Alumkal, Rachel Slottke, Jacob Schwartzman, et al.
Urologic Oncology|November 10, 2019
Real-world practice patterns in veterans with metastatic castration-resistant prostate cancerAhmad S Halwani, Kelli M Rasmussen, Vikas Patil, et al.
Neuroscience Letters|May 4, 2000
No association between TAU haplotype and Alzheimer's disease in population or clinic based series or in familial diseaseM Baker, D Graff-Radford, F Wavrant DeVrièze, et al.
The Lancet. Oncology|September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialFred Saad, David Cella, Ethan Basch, et al.
Human Molecular Genetics|November 5, 1997
A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43)C B Eckman, N D Mehta, R Crook, et al.
European Urology Focus|September 4, 2021
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation TherapyStéphane Oudard, Boris Hadaschik, Fred Saad, et al.
Nature|March 24, 2022
Androgen receptor activity in T cells limits checkpoint blockade efficacyXiangnan Guan, Fanny Polesso, Chaojie Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2019
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancerE J Small, F Saad, S Chowdhury, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide aloneJulie N Graff, Tomasz M Beer, Joshi J Alumkal, et al.
Pageof 11

Showing results (71-80 of 104) with videos related to

Sort By:
Pageof 11
Neurology|April 28, 2012
Genotype patterns at PICALM, CR1, BIN1, CLU, and APOE genes are associated with episodic memoryS Barral, T Bird, A Goate, et al.
Investigational New Drugs|November 29, 2014
A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancerJoshi J Alumkal, Rachel Slottke, Jacob Schwartzman, et al.
Urologic Oncology|November 10, 2019
Real-world practice patterns in veterans with metastatic castration-resistant prostate cancerAhmad S Halwani, Kelli M Rasmussen, Vikas Patil, et al.
Neuroscience Letters|May 4, 2000
No association between TAU haplotype and Alzheimer's disease in population or clinic based series or in familial diseaseM Baker, D Graff-Radford, F Wavrant DeVrièze, et al.
The Lancet. Oncology|September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialFred Saad, David Cella, Ethan Basch, et al.
Human Molecular Genetics|November 5, 1997
A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43)C B Eckman, N D Mehta, R Crook, et al.
European Urology Focus|September 4, 2021
Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation TherapyStéphane Oudard, Boris Hadaschik, Fred Saad, et al.
Nature|March 24, 2022
Androgen receptor activity in T cells limits checkpoint blockade efficacyXiangnan Guan, Fanny Polesso, Chaojie Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2019
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancerE J Small, F Saad, S Chowdhury, et al.
Journal for Immunotherapy of Cancer|July 4, 2020
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide aloneJulie N Graff, Tomasz M Beer, Joshi J Alumkal, et al.
Pageof 11